CMBA
CRVS icon

C.M. Bidwell & Associates’s Corvus Pharmaceuticals CRVS Stock Holding History

C.M. Bidwell & Associates’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-234
Closed -$3K – 241
2016
Q4 		$3K Sell
234
-8,356
-97% -$127K ﹤0.01% 226
2016
Q3 		$141K Buy
+8,590
New +$124K 0.03% 196

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

C.M. Bidwell & Associates's CRVS Position: Q1 2017 in Review

C.M. Bidwell & Associates sold out of Corvus Pharmaceuticals (CRVS) in Q1 2017, closing a stake of 234 shares — an estimated $3K sold.

C.M. Bidwell & Associates first reported a position in CRVS in Q3 2016 and held it in 2 quarters. The position peaked at $141K in Q3 2016. 52 funds tracked by Wall St. Rank hold CRVS as of Q1 2017.

  • C.M. Bidwell & Associates reported no remaining Corvus Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • C.M. Bidwell & Associates sold 234 Corvus Pharmaceuticals shares in Q1 2017, an estimated $3K.
  • C.M. Bidwell & Associates first reported a position in Corvus Pharmaceuticals in Q3 2016 and held it in 2 quarters.
  • C.M. Bidwell & Associates's Corvus Pharmaceuticals position peaked at $141K in Q3 2016.
  • 52 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2017.

Based on C.M. Bidwell & Associates's 13F filing for Q1 2017, filed 12 May 2017.